The STING1 network regulates autophagy and cell death
Ruoxi Zhang1, Rui Kang1 and Daolin Tang1

INTRODUCTION
Pathogen-associated molecular patterns (PAMPs) derived from microorganisms and damage-associated molecular patterns (DAMPs) produced by host cells are recognized by pattern recognition receptors (PRRs), which play a fundamental role in innate immunity during infection and tissue damage1-5. Major PAMPs include microbial nucleic acids (DNA and RNA) and membrane components (e.g., lipopolysaccharide [LPS]), whereas the host DNA is an important DAMPs. Dysregulation of DNA-sensing pathways is implicated in various diseases, such as autoimmune diseases and cancer. In 2008 and 2009, stimulator of interferon response cGAMP interactor 1 (STING1, also known as STING, TMEM173, MITA, or MPYS) was identified that cyclic GMP-AMP synthase (CGAS) is a direct cytosolic DNA sensor that elicits robust innate immune responses through STING17. These studies have established a new DNA recognition pathway in the innate immune system8,9. STING1 is an evolutionarily conserved transmembrane protein that localizes to the endoplasmic reticulum (ER) membrane in immune and non-immune cells. As an adapter protein, STING1 can be directly activated by bacterial cyclic dinucleotides (CDNs, such as cyclic-di-GMP and cyclic-di-AMP) or the second messenger cyclic guanosine monophosphate-adenosine monophosphate (cGAMP)10,11, a process that is involved in inflammation and immune response by producing type I interferons (IFNs) and pro-inflammatory cytokines18. The cGAMP is produced from CGAS, which detects and binds DNA substrates from invading pathogens (e.g., DNA viruses, retroviruses, and bacteria) or damaged hosts (including mitochondrial DNA [mtDNA] and nuclear DNA [nDNA]) during various stresses12 (Fig. 1). In addition, cGAMP or host DNA can be transferred between cells and activate STING1 through channels and transporters13-15, dying cell debris, or DNA-containing extracellular vesicles16. In addition to cytoplasmic CGAS, plasma membrane receptors (such as epidermal growth factor receptor [EGFR] and ALK receptor tyrosine kinase [ALK]) can also activate STING1 in response to exogenous cGAMP or CDNs in immune cells17. Overall, these findings indicate that the activation of STING1 can be induced by both CGAS-dependent and -independent pathways.

After activation, STING1 on the ER undergoes oligomerization18, leaving the ER through the chromosome X open reading frame 56 (CxORF56) and coat protein complex II (COPII)19-21, and finally translocating to the Golgi apparatus through the endoplasmic reticulum-Golgi intermediate compartment (ERGIC)22 (Fig. 1). In the Golgi, palmitoylated STING1 recruits TANK binding kinase 1 (TBK1)19,23, and TBK1 further transphosphorylates the C-terminal tail of STING1 to recruit interferon regulatory factor 3 (IRF3) for phosphorylation24. Phosphorylated IRF3 translocates to the nucleus and triggers the expression of immune stimulated genes (ISGs) and type I IFNs, resulting in the activation and migration of immune cells (including dendritic cells [DCs], T cells, and natural killer [NK] cells) to the target cells25. Alternatively, STING1 also activates nuclear factor kappa B subunit 1 (NFKB1)-driven inflammatory cytokine (e.g., tumor necrosis factor [TNF] and interleukin 6 [IL6]) production. As a negative feedback mechanism, the degradation of cGAMP, CGAS, or STING1 at various levels can limit type I IFN responses27,28. Functionally, the activation of this classical STING1 pathway bridges innate and adaptive immunity in response to PAMPs or DAMPs. Consequently, an insufficient or excessive activation of the STING1 pathway is implicated in various pathological conditions, such as tumorigenesis, infection, disseminated intravascular coagulation, autoimmune conditions, and tissue damage3,5,6,9,17,29-34.

Beyond the canonical role of STING1 in mediating cytokine production, growing evidence highlights the emerging role of STING1 in regulating autophagy and cell death. In this review, we focus on new discoveries about the regulation mechanisms and outcomes of STING1 in autophagy and cell death, which provide another framework to understand the biological function of STING1 in health and disease.
STING1 IN AUTOPHAGY

Autophagy is a degradation process that can be classified into three types: macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy) is the most studied form of autophagy and regulates homeostasis by either promoting survival or inducing cell death. Autophagy is also closely related to inflammation and immune response. Here, we not only outline the basic process of autophagy, but also discuss the interaction between STING1 activation and autophagy induction.

Membrane dynamics during autophagy

The process of autophagy involves the formation of membrane structures, especially phagophores, autophagosomes, and autolysosomes. This dynamic membrane process can be roughly divided into five consecutive phases: initiation, nucleation, expansion, fusion, degradation, and recycling, and is controlled by autophagy-related (ATG) family proteins, kinases, and lipid metabolism. The initiation step is triggered by inhibiting mechanistic target of rapamycin kinase (MTOR) or activating AMP-activated protein kinase (AMPK), leading to the assembly and activation of the ULK complex (including unc-51-like autophagy activating kinase 1/2 [ULK1/2, orthologs of yeast Atg1], ATG13, ATG101, and RB1 inducible coiled-coil [RB1CC1/FIP200]) and subsequent the class III phosphatidylinositol 3-kinase (PtdIns3K) complex (containing PIK3C3 [phosphatidylinositol 3-kinase catalytic subunit type 3, an ortholog of yeast Vps34], beclin 1 [BECN1, a mammalian homolog of yeast Vps30/Atg6], ATG14L [autophagy-related protein 14-like protein], and PIK3R4 [phosphoinositide 3-kinase regulatory subunit 4, a mammalian homolog of yeast Vps15]). The PtdIns3K complex-mediated production of phosphatidylinositol 3-phosphate (PtdIns3P) leads to the recruitment of PtdIns3P-binding ATG proteins, WD repeat domain phosphoinositide-interacting (WIPI) proteins, and ATG9-containing vesicles, thereby supporting phagophore nucleation (mostly at the ER). In addition to regulating autophagy, BECN1 is also a multifunctional protein in cell death through different binding partners. To promote the expansion and closure of the phagophore membrane, two ubiquitin-like conjugation pathways are needed to mediate the conjugation of microtubule-associated protein 1 light chain 3 (MAP1LC3, an ortholog of yeast Atg8) and phosphatidylethanolamine (PE). This process is called MAP1LC3 lipidation, which is controlled by many ATGs. The E1-like enzyme ATG7, the E2-like enzyme ATG3, and the cyssteine protease ATG4 lead to the

Fig. 1 The CGAS-STING1 pathway. A critical cytosolic DNA sensor, CGAS elicits robust innate immune responses through the production of 2′,3′-cGAMP, which binds and activates STING1 in response to DNA from pathogens or hosts. In addition, bacteria-produced CDNs can directly activate STING1 in a CGAS-independent manner. Activated STING1 exits the ER membrane and travels to Golgi via the ERGIC, leading to the production of type I IFNs by activating the TBK1-IRF3 pathway. STING1 also activates NFkB1-dependent pro-inflammatory cytokine expression. CDNs cytosolic cyclic dinucleotides, cGAMP cyclic GMP-AMP, CGAS cyclic GMP-AMP synthase, ER endoplasmic reticulum, ERGIC endoplasmic reticulum-Golgi intermediate compartment, IFN interferon, IKK IκB kinase, IRF3 interferon regulatory factor 3, NFkB1 nuclear factor kappa B subunit 1, STING1 stimulator of interferon response cGAMP interactor 1, TBK1 TANK binding kinase 1
formation of MAP1LC3-II. The ATG7 and the E2-like enzyme ATG10 catalyze the formation of the ATG12-ATG5-ATG16L1 complex, which binds to WIPI and functions as an E3-like ligase to mediate the lipidation of MAP1LC3-II. Lipidated MAP1LC3-II also enables the assembly of phagophores with autophagic cargo receptors (e.g., sequestosome 1 [SQSTM1/p62]) to engulf cytoplasmic materials. The closure of the phagophore results in the formation of double-membrane structures, namely autophagosomes. Autophagosomes finally fuse with lysosomes to produce autolysosomes, where the cargoes are degraded. The subsequent degradation of autophagic cargoes by lysosomal hydrolases leads to the release of nutrients and materials back to the cytoplasm for reuse. Overall, from yeasts to plants and animals, membrane dynamics during autophagy are highly conserved.

STING1-mediated autophagy prevents pathogen infection Since it was first documented that ATG9a and STING1 co-localized in vesicles and restricted dsDNA-induced IFN production in mouse embryonic fibroblasts (MEFs)45, accumulating evidence has enabled us to understand how STING1 plays context-dependent roles in the induction and regulation of autophagy under different stresses. In general, pathogenic DNA can activate STING1 and subsequent autophagy to restrict pathogen infection by removing bacteria and viruses.5,46, as described below.

During Mycobacterium tuberculosis infection, STING1 is activated by CGAS, triggering ubiquitin-mediated selective autophagy (namely xenophagy) by SQSTM1, ATG5, and TBK1 in macrophages to eliminate M. tuberculosis11,47. In contrast, c-di-AMP induces STING1-dependent autophagy via MTOC inactivation in macrophages during Gram-positive bacterial infection51, whereas the deletion of ULK1, RB1CC1, and ATG14L can limit MAP1LC3 lipidation during this process. Similar to bacterial infection, during herpes simplex virus 1 (HSV-1) infection, cytosolic viral DNA triggers STING1-dependent autophagy in bone marrow-derived DCs.56 Further studies using Sting1 mutant mice suggest that STING1-mediated autophagy (but not STING1-dependent IFN production) is responsible for anti-HSV-1 responses52, although HSV may also counter this STING1-mediated autophagy induction in vivo.53 This autophagy-dependent antiviral function is also observed in human rhinovirus (HRV)-infected HeLa cells after treatment with the STING1 agonist dimeric amido-benzimidazole (diABZI)53, although it is unclear whether CGAS is required for this process.

STING1-mediated autophagy during infection is also related to NF-kB signaling. For example, NF-kB-mediating STING1 expression triggers autophagy in the adult fly brain against Zika virus (ZIKV) infection55. Moreover, NF-kB mediates the expression of DNA damage-regulated autophagy modulator (DRAM1), thereby inducing selective autophagy in zebrafish and human macrophages during M. tuberculosis infection, and this process is positively regulated by STING1.56 STING1 can also recognize and degrade the contents of lytic Chlamydiae trachomatis in HeLa cells through a selective autophagy pathway57. Moreover, the antibacterial protein IL-26 secreted by TH17 cells can induce STING1-dependent autophagy to eliminate invasive Mycobacterium leprae in TH-1 cells.58 Together, STING1-dependent autophagic clearance of invading pathogens may be an important host defense mechanism against infection. However, the interplay between STING1-dependent xenophagy and cytokine production remains uncertain.

STING1-mediated autophagy limits tumor growth and transformation
In addition to promoting survival, excessive autophagy may also lead to cell death, known as autophagy-dependent cell death (ADCD)59. Although ADCD is also a type of regulated cell death (RCD) according to the recommendation of the Nomenclature Committee on Cell Death60, it relies on components of autophagic machinery and takes place in the context of apoptosis51, necroptosis62-64, and ferroptosis65-69. Two studies on pancreatic cancer cells have linked DNA damage, STING1 activation, and autophagy-dependent ferroptosis. The nucleoside analog zalcitabine (an antiviral drug) induces oxidative mtDNA damage and the release of mtDNA into cytosol, resulting in the activation of the CGAS-STING1 pathway, which in turn induces autophagy-dependent ferroptosis and suppresses pancreatic tumor growth in mice.70 In addition to mtDNA, the release of nDNA to cytosol caused by nuclear cathepsin B (CTSB)-mediated genomic DNA damage activates STING1-dependent autophagy and subsequent glutathione peroxidase 4 (GPX4) degradation, leading to ferroptotic cell death in human pancreatic cancer cells71. These findings provide an example of how lysosomal proteins can drive STING1 activation for autophagy-dependent ferroptosis.

Reproductive crisis is a senescence-independent process, characterized by chromosomal instability72. It functions as a potent tumor suppressor against oncogenic transformation and tumorigenesis and culminates in extensive cell death, which is modulated by telomeric damage signals72,73. When replicative crisis occurs, increased telomere DNA damage also initiates CGAS-STING1-dependent ADCD to limit genome instability in human mammary epithelial cells and IMR90667 cells.74. These results demonstrate tumor suppressive roles for STING1-dependent ADCD during transformation. Accordingly, Burkholderia pseudomallei-induced cell fusion triggers mitotic events and subsequent micronuclear formation, which leads to CGAS-STING1 activation and ultimately STING1-dependent ADCD in macrophages75, suggesting that ADCD acts as a natural defense against cellular transformation and unnatural cellular fusions.

Overall, these in vitro and in vivo data indicate that STING1 activation induced by host DNA damage can trigger ADCD to remove cancer cells or other stressed cells. It will be interesting to see whether the activation of STING1-dependent autophagy plays a direct role in degrading DNA or micronucleus in damaged cells, a process called DNAphagy.

The mechanism of STING1 regulates the autophagy pathway
The autophagy mediated by STING1 is a selective process that requires specific signals and regulators in a context-dependent manner (Fig. 2). After binding to cGAMP, STING1 leaves the ER and is transported to the ERGIC, which serves as a membrane source for autophagosome biogenesis.71 STING1-mediated autophagosome formation is generally independent of the activation of TBK1 and IRF321,22,52,76 as well as ULK1, BECN1, and PIK3C321,76 Moreover, although ATG9a is a regulator of STING1 trafficking and activation of autophagy77, it is dispensable for STING1-dependent autophagy.78 These findings suggest that STING1 initiates a noncanonical form of autophagy driving autophagosome formation. Subsequent studies have highlighted that WD repeat domain, phosphoinositide-interacting 2 (WIP2), ATG5, and ATG7 are required for STING1-induced autophagosome formation79, whereas RAB7A promotes the transport of STING1 to lysosomes through autophagosomes and endosomes79,80. Finally, STING1 can be self-degraded by autophagy machinery, which requires the use of the TBK1 signal and autophagy receptor SQSTM1 in MEFs and TH-1 cells75,81, while SQSTM1 and TBK1 are required for STING1- and ubiquitin-mediated selective autophagy targeting M. tuberculosis in macrophages79. Alternatively, since TBK1 is not required for STING1-induced autophagy in HeLa cells, STING1 can function as an autophagy receptor itself that directly binds with MAP1LC3 via its LIR motifs in a SQSTM1-independent manner.76 Consistently, the lack of ATG5 or WIP2 abolishes SQSTM1 degradation (but not STING1 degradation) in cGAMP-treated BJ cells75. In addition, extracellular SQSTM1 is an inflammatory mediator in mice with bacterial infections, and the lysosome-dependent release of SQSTM1 induced by LPS in macrophages is initiated by STING1–TBK1–mediated
phosphorylation of SQSTM1 on Ser 403.31. These findings confirm that STING1 is not only an autophagy substrate, but also a modulator of autophagy during infection, which shapes host defense response, coupled to signals via SQSTM1 release.

In other cases, a BECN1-related PtdIns3K complex may contribute to STING1-dependent ADCD in HeLa cells during Chlamydiae infection.57. Bacterial c-di-AMP activates STING1 and triggers ER stress, leading to MTOR inactivation and subsequent ER-phagy in macrophages.51. Considering that STING1 is widely involved in ER calcium homeostasis79 and the unfolded protein response80, it is possible that STING1 activation may also trigger autophagy through ER stress and the MTOR-BECN1 pathway (Fig. 2).

Moreover, the activation of STING1 by cGAMP also induces V-ATPase-dependent MAP1LC3 lipidation to single-membrane perinuclear vesicles through ATG16L1.81, suggesting an additional function of STING1 in membrane dynamics. In line with this, STING1 was observed to increase PI3P production and ER membrane curvature and to cluster at ER curvature-rich regions after cGAMP stimulation.19. HRV replication also requires that STING1 is expressed on phosphatidylinositol 4-phosphate (PI4P)-enriched replication organelles.82. Given that the IFN-dependent C-terminal tail region is not required for STING1 to induce autophagy,21,27, it is possible that STING1 contributes to a wide range of cellular functions via membrane dynamics and ER exit trafficking in an IFN-independent manner. Of note, the activation of STING1 by lipotoxicity induced by saturated fatty acids may inhibit hepatocyte autophagy, which is related to the increase of SQSTM1 phosphorylation and oxidative stress83. The precise role of STING1 in autophagy regulation should be carefully evaluated under different stress conditions.

The mechanism of autophagy modulating the STING1 pathway The function of STING1 in immunity is also dually regulated by autophagic degradation or components of autophagy machinery. On one hand, autophagy restricts the activation of the STING1 pathway through multiple mechanisms (Fig. 2). First, autophagy can remove radiation-caused cytosolic mtDNA accumulation in breast cancer cells.84. Second, AMPK and ULK1 mediate the phosphorylation of STING1 on S366, leading to the degradation of STING1 and inhibition of IFN production.85,86. Consistently, the inactivation of ULK1 enhances the STING1-mediated innate immune response in keratinocytes under UV treatment.87. Third, the autophagic degradation of STING1 in lysosomes by V-ATPase diminishes STING1 activation.21,27. In contrast, blocking STING1 degradation by the V-ATPase inhibitor bafilomycin A enhances STING1-mediated immune signaling and antitumor response. Fourth, BECN1 is a negative regulator of STING1, which partially affects the phosphorylation of STING1 by binding to STING1.88,89. Given that BECN1 and STING1 can bind to ER Ca2+ channel inositol 1,4,5-trisphosphate receptors (ITPRs/InsP3Rs) to promote the release of Ca2+ from the ER,99,100 they may form a complex on the ER that controls autophagosome formation by ITPR-mediated Ca2+ signaling. Fifth, the pharmacological or genetic inhibition of ATG9a augments STING1-dependent IFN production.10,91. On the other hand, a few studies show that the knockdown of PIK3C3 inhibits STING1 trafficking and activation.92

Fig. 2 Crosstalk between STING1 and autophagy. a The activation of STING1 by bacterial CDNs triggers autophagy through ER stress or the MTOC-ULK1-BECN1 pathway. b cGAMP binds to STING1, causing it to be translocated from the ER to the ERGIC and Golgi. The ERGIC serves as a membrane source for the recruitment and lipidation of MAP1LC3 through an ATG5-, ATG7-, and WIPI2-dependent mechanism, leading to autophagosome formation. Autophagosomes engulfing DNA and pathogens target STING1 in an SQSTM1-dependent or -independent manner. c Activated STING1 can translocate to endosomes through the trans-Golgi network. Both the endosomes and autophagosomes fused with lysosomes require RAB7A GTPase. d STING1-mediated IFN response is also negatively regulated by autophagic degradation or ATGs (including ULK1, BECN1, and ATG9a). AMPK AMP-activated protein kinase, ATG autophagy-related, BECN1 beclin 1, CDNs cytosolic cyclic dinucleotides, cGAMP cyclic GMP-AMP, ER endoplasmic reticulum, ERGIC endoplasmic reticulum-Golgi intermediate compartment, IFN interferon, MAP1LC3 microtubule-associated protein 1 light chain 3, MTOC mechanistic target of rapamycin kinase, PE phosphatidylethanolamine, PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3, RAB7A, member RAS oncogene family, SQSTM1 sequestosome 1, STING1 stimulator of interferon response cGAMP interactor 1, TBK1 TANK binding kinase 1, ULK1 unc-51–like autophagy activating kinase 1, WIPI2 WD repeat domain phosphoinositide-interacting 2.
Thus, it remains a challenge to distinguish the autophagy-dependent and -independent roles of ATG in regulating the activation of the STING1 pathway.

**STING1 IN CELL DEATH**

RCD is an active process involving tightly structured signal transduction cascades, molecularly defined effector mechanisms, and membrane repair machineries\(^{52–97}\). It has many forms, such as but not limited to apoptosis, necroptosis, pyroptosis, ferroptosis, ADCD, and immunogenic cell death (ICD)\(^9\), and plays a vital role in various physiological or pathological processes, including tissue regeneration, infection, immunity, and tumorigenesis\(^9\). Such a homeostatic function not only reflects the elimination of damaged or aged cells, but also the ability of dying cells to expose or release DAMPs that activate immune responses\(^{100–103}\). Recent evidence indicates that STING1 not only mediates cell death, but also plays a role in recognizing and amplifying the immune response induced by dying cells.

**STING1 in apoptosis**

Apoptosis is usually a type of immune-silent RCD because it has a limited ability to release contents and can be quickly cleared by phagocytes (a process also known as effecrocytosis). The activation of apoptosis generally includes two distinct pathways: the death receptor (or extrinsic) and the mitochondrial (or intrinsic) pathways. In many cases, caspases (cysteine-dependent proteases), such as caspase 3 (CASP3), CASP6, and CASP7, are effectors of apoptosis by mediating the cleavage of structural proteins\(^{104,105}\). The mitochondrial apoptosis pathway is initiated by various stresses, leading to increased mitochondrial outer membrane permeability (MOMP) and the release of mitochondrial proteins, such as cytochrome C, somatic (CYCS). Cytosolic CYCS binds to apoptotic peptidase activating factor 1 (APAF1), leading to the activation of CASP9 and subsequent executioner caspases CASP3 and CASP7, and ultimately causing apoptosis\(^{60,106}\). The interaction of anti-apoptotic or pro-apoptotic BCL2 family members orchestrates MOMP and has become a therapeutic target in clinical trials\(^107\). The death receptors include Fas receptors, TNF receptors, and TNF-related apoptosis-inducing ligand (TRAIL) receptors, which can recruit the adapter protein Fas associated via death domain (FADD) to active CASP8 or CASP10, and ultimately lead to apoptosis by activating CASP3 or CASP7\(^{108}\). In contrast, the mechanism and function of caspase-independent apoptosis remains poorly understood.

The activation of STING1 during apoptosis was first reported in 2014 by two groups. They found that mitochondrial apoptosis mediated by BCL2-associated X, apoptosis regulator (BAX), and BCL2 antagonist/killer 1 (BAK1) leads to mtDNA release and subsequently the activation of the CGAS-STING1 pathway in CASP9-deficient cells, which contributes to the inflammatory response\(^{109,110}\). Further studies confirm that BAX/BAK1-mediated MOMP is required for mtDNA-dependent STING1 activation\(^{111,112}\), while active CASP3 can cleave CGAS or IRF3 to prevent excessive IFN production\(^ {113}\). Consistently, the depletion of transcription factor A, mitochondrial (TFAM, a mtDNA binding protein essential for genome maintenance) also induces mtDNA-mediated inflammation by activating STING1 in renal tubule cells\(^{114}\) (Fig. 3). Moreover, STING1 facilitates apoptotic DNA-induced pro-inflammatory gene expression in hematopoietic cells or apoptosis-derived membrane

---

**Fig. 3** STING1 in apoptosis, mitotic cell death, and necroptosis. **a** In response to mtDNA, nDNA, or ER stress, STING1 activates IRF3. IRF3 can increase BAX/BAK1-mediated MOMP by forming an IRF3-BAX complex or inhibiting BCL2L1, leading to caspase activation and ultimately apoptosis. In turn, increased apoptosis double-regulates the STING1-IRF3 pathway by releasing mtDNA or activating CASP3-mediated cleavage of CGAS or IRF3. **b** STING1 triggers necroptosis by cooperating with downstream type I IFN-mediated MLKL expression and TNF-induced phosphorylation of RIPK1 and RIPK3. APAF1 apoptotic peptidase activating factor 1, BAK1 BCL2 antagonist/killer 1, BAX BCL2-associated X, apoptosis regulator, BCL2L1 BCL2-like 1, CASP caspase, CGAMP cyclic GMP-AMP, CGAS cyclic GMP-AMP synthase, CYCS cytochrome C, ER endoplasmic reticulum, FADD Fas associated via death domain, IFN interferon, IMM inner mitochondrial membrane, IRF3 interferon regulatory factor 3, MLKL mixed-lineage kinase domain-like pseudokinase, MOMP mitochondrial outer membrane permeability, NFkB1 nuclear factor kappa B subunit 1, RIPK1 receptor interacting serine/threonine kinase 1, RIPK3 receptor interacting serine/threonine kinase 3, STING1 stimulator of interferon response cGAMP interactor 1, TBK1 TANK binding kinase 1, TNF tumor necrosis factor
vesicle (AdMV)-induced type I IFN expression in THP-1 cells. In addition, apoptotic tumor cells activate the STING1 pathway in tumor-associated macrophages (TAMs), thereby enhancing antitumor immune responses. These studies from different groups suggest that apoptotic cells can activate STING1 to produce inflammation or an immune response.

The activation of STING1 also determines the sensitivity to apoptosis in a context-dependent manner. For example, STING1 agonists can trigger apoptosis in malignant B cells, neuroblastoma cells, and cancerous T cells but not in MEFs, bone marrow-derived DCs, and bone marrow-derived macrophages (BMDMs). In a sepsis mouse model, elevated mtDNA induces STING1-dependent apoptosis in intestinal epithelial cells (Fig. 3). Interestingly, both STING1 deficiency and activation promote the polarization of TAMs into a pro-inflammatory subtype, thereby inducing apoptosis in gastric cancer cells through the IL6R-JAK–conserved motif within CDN binding domain, which is also crucial for STING1 activation by gain-of-function mutation enhances the sensitivity of T cells to apoptosis through ER-related calcium signaling. Third, Mycobacterium bovis infection in RAW.247 cells or ethanol treatment in hepatocytes triggers ER stress and subsequently STING1-dependent apoptosis.

The mechanism of STING1-mediated apoptosis is mainly related to ER stress based on several findings. First, STING1-dependent apoptosis occurs simultaneously with increases in spliced X-box binding protein 1 (XBP1, a marker of ER stress) in T cells whereas the genetic or chemical inhibition of spliced XBP1 impairs STING1-mediated apoptosis in B cells. Second, the constitutive activation of STING1 by gain-of-function mutation enhances the sensitivity of T cells to apoptosis through ER-related calcium signaling. Third, Mycobacterium bovis infection in RAW.247 cells or ethanol treatment in hepatocytes triggers ER stress and subsequently STING1-dependent apoptosis.

In addition to ER signaling, STING1-mediated apoptosis may require the activation of the IRF3 pathway in some conditions. These conditions include free fatty acid-induced L-O2 cells, retrovirus-infected primary human monocytes, Mycobacterium bovis-infected RAW.247 cells, LPS-infused cardiomycocytes, and ethanol-treated hepatocytes. Mechanically, STING1-mediated phosphorylation of IRF3 triggers the formation of the IRF3-BAX complex, which leads to BAX activation, CYCS release, and apoptosis. These findings raise concerns about the mitochondrial function of IRF3 in innate immunity.

Taken together, the STING1-IRF3 pathway engages in both apoptosis-derived immune response and apoptosis induction, and this pathway can be regulated by apoptotic caspases, while the interplay and feedback mechanism between STING1, ER stress, and apoptosis is definitely complex.

STING1 in necroptosis

Necroptosis is a form of regulated necrosis in which caspase is inhibited. It can be triggered by the activation of death receptors or PRRs, such as toll-like receptor 3 (TLR3), TLR4, and Z-DNA binding protein 1 (ZBP1/DAI). The core regulator of necroptosis is involved in the formation of necroosome, which is composed of three core components: receptor interacting serine/threonine kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like pseudokinase (MLKL). After being activated by RIPK1 and RIPK3, phosphorylated MLKL oligomerizes and destroys the plasma membrane, leading to necrotic cell death.

The activation of STING1 is related to necroptotic stimulation. In sporadic aortic aneurysm and dissection tissue, increased stress in smooth muscle cells causes the release of mtDNA and nDNA into the cytosol, resulting in the activation of the CGAS-STING1 pathway and necroptosis. A deficiency of STING1, TBK1, or IRF3 reduces, whereas the overexpression of STING1 and TBK1 increases, the phosphorylation of RIPK3 and MLKL, indicating that the STING1-IRF3-RIPK3-MLKL pathway drives necroptosis by a phosphorylation mechanism. Given that IFNβ is required for RIPK3 activation and necroptosis in macrophages, STING1 may also contribute to necroptosis by IFN production. Indeed, the constitutive activation of the CGAS-STING1 pathway instead of ZBP1 in macrophages elevates MLKL expression and necroptosis through IFNβ. In addition, BCL2 binding component 3 (BBC3/PUMA)-induced mtDNA release activates STING1-dependent necroptosis by elevating the expression of RIPK3 and MLKL in HT29 colon cancer cells and MEFs. These data also indicate that MLKL is an expression of STING1-dependent ISGs, providing an additional transcription-mediated modulation mechanism of necroptosis.

However, the overexpression of MLKL alone could not restore necroptosis in IFN receptor-deficient macrophages, implying other STING1-dependent downstream products may mediate MLKL phosphorylation for necroptosis. In agreement with this hypothesis, TNF production is also involved in STING1-mediated necroptosis based on four independent studies. First, anti-TNF neutralizing antibody inhibits murine gammaherpesvirus-68 (MHV)-induced necroptosis in the fibrosarcoma L929 cell line in a STING1-dependent manner. Second, the activation of CGAS-STING1 in vivo and in vitro can lead to RIPK3-mediated necroptosis, which requires STING1-dependent type I IFN and TNF production. Third, IL-22 induces STING1-dependent type I IFN and TNF expression in mouse small intestine organoids, driving necrosis. Fourth, mtDNA-mediated STING1 signaling triggers necroptosis through synergistic IFN and TNF signaling in primary intestinal epithelial cells. In sum, these data indicate that STING1 signaling triggers necroptosis through at least two mechanisms, inducing MLKL expression or MLKL phosphorylation.

STING1 in pyroptosis

Pyroptosis is a caspase-dependent RCD driven by pore formation protein gasdermin D (GSDMD) or gasdermin E (GSDME/DFN5). During inflammasome activation or other stresses, GSDMD can be cleaved by CASP1, CASP11 (also known as CASP4 or CASP5 in humans) or CASP8 to produce N-terminal fragment of GSDMD (GSDMD-N). In contrast, the production of GSDME-N is mediated by CASP3. After oligomerization, GSDMD-N or GSDME-N forms pores in the plasma membrane, leading to pyroptotic cell death. Inflammasomes are divided into two categories: canonical and noncanonical. Canonical inflammasomes complexes are assembled in response to signaling from cytosolic PRRs, such as NLR family pyrin domain containing 3 (NLRP3) and absent in melanoma 2 (AIM2). These PRRs sense PAMPs or DAMPs to recruit the adapter protein PYD and CARD domain containing (PYCARD/ASC), leading to CASP1 activation and subsequent pyroptosis. Noncanonical inflammasomes is mainly triggered by cytoplasmic LPS-induced CASP11 or CASP4/5 activation, resulting in the production of GSDMD-N and pyroptosis. As a feedforward control, the GSDMD pores allow potassium efflux, promoting the activation of NLRP3 inflammasome, which then causes the release of IL1 family cytokines or DAMPs. STING1 promotes cGAMP-induced NLRP3 inflammasome activation in macrophages, cardiomyocytes, and mice following LPS challenge. In addition, Mycobacterium abscessus infection in murine macrophages triggers mitochondrial oxidative stress and leads to the activation of the CGAS-STING1 pathway and NLRP3 inflammasome activation while the inhibition of STING1 suppresses NLRP3 activation in mtDNA-stimulated BMDMs from aged mice. In terms of mechanisms, three pathways may contribute to STING1-dependent inflammasome activation and pyroptosis (Fig. 4). First,
infection. However, the conditional depletion of GPX4 in myeloid cells increases death caused by bacterial infection in mice, suggesting a different role of GPX4 in bacterial innate immunity. Moreover, mitochondrial or genomic DNA stress activates STING1-dependent autophagy in pancreatic cancer cells, which may cause lipid peroxidation-mediated ferroptosis. Although the mechanism remains obscure, STING1-dependent autophagy may degrade GPX4, promoting ferroptosis (Fig. 5). Accordingly, a robust STING1 activation produces excessive lipid peroxidation during ischemia/reperfusion injury, which is associated with cell death in BMDMs. Thus, the STING1-related ferroptosis pathway is a potential therapeutic target of cancer and tissue damage.

STING1 plays a dual role in tumor immunity. An acute activation of STING1 is beneficial for antitumor therapy, and chronic activation of STING1 may mediate inflammation that supports tumor growth. Consistent with this idea, ferroptotic damage promotes 8-hydroxy-2′-deoxyguanosine (8-OHG, an oxidized nucleobase product of oxidative DNA damage) release, thereby activating STING1-dependent macrophage polarization. By maintaining inflammation-related tumorigenesis, this chronic activation of STING1 triggered by ferroptotic DNA damage ultimately promotes KRAS-driven pancreatic ductal adenocarcinoma in mice (Fig. 5), highlighting the dark side of ferroptosis in tumor immunity. Further research is needed to clarify the role of STING1 in regulating ferroptosis in different immune cells within the tumor microenvironment.

STING1 in mitotic death
Mitotic death is a specific variant of RCD driven by mitotic catastrophe, which suppresses the proliferation of cells undergoing aberrant mitosis. It usually ends with the formation of large cells with multiple micronuclei and decondensed chromatin. Ruptured micronuclei can be recognized by CGAS during genome instability to activate an innate immune response. To avoid hyperactivation, CGAS is normally inhibited by nucleosomes.

During mitotic arrest, CGAS triggers the activation of STING1 and IRF3 in response to the increase of micronuclei, which leads to the transcriptional upregulation of NLRP3, requiring the production of STING1-mediated IRF3 in a TLR4-dependent manner. Second, STING1 can directly bind and promote NLRP3 localization in the ER, thereby inhibiting NLRP3 ubiquitin degradation. Third, in response to cytosolic DNA in human myeloid cells, the CGAS-STING1 pathway instead of AIM2 activates potassium efflux-mediated NLRP3 inflammasome via lysosomal STING1-mediated lysosomal cell death. Consistent with this, G10 (an agonist of STING1) induces potassium efflux and NLRP3 activation in porcine cells. Conversely, the inhibition of NLRP3 inflammasomes increases STING1-dependent IFN production, while the activation of NLRP3 or AIM2 in murine macrophages leads to the inactivation of the STING1 pathway during ischemia/reperfusion injury, which is associated with cell death in BMDMs.

Thus, the STING1-related ferroptosis pathway is a potential therapeutic target of cancer and tissue damage.
which is related to the excessive activation of autophagy.

Burkholderia pseudomallei infection also causes STING1-dependent mitotic death, previously increased telomeric DNA damage or (but not DCs) through purinergic receptor P2X 7 (P2RX7) channels, carcinoma cells, neuroblastoma cells, and melanoma cells agonists stimulates ICD-mediated antitumor immunity in colon carcinoma cells.

The effective activation of STING1 by various pharmacological approaches (Table 1), our understanding of the regulation and function of STING1 has rapidly improved. Consequently, STING1 inhibitors (Table 1) can alleviate the side effects of STING1 overactivation.

In addition to the traditional function of STING1 in mediating inflammation and immune response, emerging evidence has revealed that STING1 is a key regulator of autophagy and cell death after its post-translational modification. For example, palmitoylation at C881/91 residues of STING1 is not only essential for maintaining active STING1 on Golgi membranes, but also for glutathione peroxidase 4 (GPX4) degradation and ferroptosis, whereas lipid peroxidation negatively regulates STING1 through carbonylation.

The STING1 network regulates autophagy and cell death

STING1 is implicated in generating antitumor adaptive immunity. During ICD, dying cells release or expose DAMPs, activate DC-mediated antigen presentation, and ultimately lead to cytotoxic T-cell responses. ICD is associated with multiple cell death modalities (e.g., apoptosis, pyroptosis, necroptosis, and ferroptosis) and can be triggered via a set of therapeutic agents and modalities (e.g., apoptosis, pyroptosis, necroptosis, and ferroptosis). ICD is associated with multiple cell death modalities (e.g., apoptosis, pyroptosis, necroptosis, and ferroptosis). ICD mediates antigen presentation, and ultimately lead to cytotoxic T-cell responses. ICD is associated with multiple cell death modalities (e.g., apoptosis, pyroptosis, necroptosis, and ferroptosis).

ICD is also induced in some cancer cells by activating the CGAS-STING1 pathway. The effective activation of STING1 by various agonists stimulates ICD-mediated antitumor immunity in colon carcinoma cells, neuroblastoma cells, and melanoma cells by producing highly immunogenic cancer cell debris or type I IFNs (Fig. 5). Moreover, DNA released from apoptotic MC38 tumor cells can stimulate a STING1-dependent type I IFN response in TAMs (but not DCs) through purinergic receptor P2X 7 (P2RX7) channels, thereby further enhancing antitumor CD8+ T-cell response (Fig. 5). Given that CGAS is constitutively active in most tumor cells and results in the production of cGAMP, which can be internalized by bystander cells through gap junctions, transporter solute carrier family 19 member 1 (SLC19A1), or volume-regulated anion channels, targeting the STING1 pathway has the potential to overcome the immunosuppressive tumor microenvironment.

CONCLUSIONS AND PERSPECTIVES

In the past 5 years, by combining genetic technology and pharmacological approaches (Table 1), our understanding of the regulation and function of STING1 has rapidly improved (Fig. 6). Accordingly, there is growing interest in the development of natural and synthetic CDN analogs as well as non-CDN small molecule STING1 agonists as clinical drugs for cancer treatment and antiviral therapy (Table 1). However, because tumor-specific T cells can initiate immunosuppressive pathways including CD274 molecule (best known as PD-L1), thereby preventing tumor clearance, activating the STING1 pathway alone (e.g., using cyclic diadenyl monophosphate) is not sufficient to kill tumors.

In addition to the traditional function of STING1 in mediating inflammation and immune response, emerging evidence has revealed that STING1 is a key regulator of autophagy and cell death after its post-translational modification. For example, palmitoylation at C881/91 residues of STING1 is not only essential for maintaining active STING1 on Golgi membranes, but also for glutathione peroxidase 4 (GPX4) degradation and ferroptosis, whereas lipid peroxidation negatively regulates STING1 through carbonylation.

The STING1 network regulates autophagy and cell death

The effective activation of STING1 by various pharmacological approaches (Table 1), our understanding of the regulation and function of STING1 has rapidly improved. Consequently, STING1 inhibitors (Table 1) can alleviate the side effects of STING1 overactivation.

In addition to the traditional function of STING1 in mediating inflammation and immune response, emerging evidence has revealed that STING1 is a key regulator of autophagy and cell death after its post-translational modification. For example, palmitoylation at C881/91 residues of STING1 is not only essential for maintaining active STING1 on Golgi membranes, but also for glutathione peroxidase 4 (GPX4) degradation and ferroptosis, whereas lipid peroxidation negatively regulates STING1 through carbonylation.
| Drugs | Targets | Effect | Model/Disease/Cancer Type | Clinical Trial Phase | Clinical Trial ID/Publication Number | References |
|-------|---------|--------|---------------------------|----------------------|--------------------------------------|------------|
| **Natural CDN agonists** | | | | | | |
| c-di-GMP | hSTING1; mSTing1 | Antitumor activity | 4T1 and B16 mouse models | | 186, 187 | |
| 2’,3’cGAMP | hSTING1; mSTing1 | Antitumor activity | CT26, 4T1, and B16F10 mouse models | | | |
| **Synthetic CDN agonists** | | | | | | |
| ML-RR-S2-CDA | hSTING1 mSTing1 | Antitumor activity | B16F10, 4T1, and CT26 mouse models | | 189 | |
| ML-RR-S2-CDG | hSTING1 mSTing1 | Antitumor activity | B16F10 mouse models | | 189 | |
| 3’,3’cAIMP | hSTING1 mSTing1 | Antiviral activity | HSV2 infection | | | |
| **Non-CDN agonists** | | | | | | |
| DMXAA | mSTING1 | Antitumor activity | Various mouse models | Failed in phase III clinical trial | | 191 |
| FAA | mSTING1 | Antitumor activity | Various mouse models | Failed in phase I clinical trial | | 192 |
| CMA | mSTING1 | Antiviral activity | Murine models | | | 193 |
| α-Mangostin | hSTING1; mSTing1 | Antitumor and antiviral activity | | | | 194 |
| ABZI | hSTING1; mSTing1 | Antitumor activity | CT26 mouse models | | | 195 |
| Benzothiophenes | hSTING1; mSTing1 | Antitumor activity | MC38 mouse models | WO2019027858 | | |
| MSA-2 | hSTING1 | Antitumor activity | MC38 mouse models | | | 196 |
| SR-717 | hSTING1; mSTing1 | Antitumor activity | B16F10 mouse models | | | 197 |
| **STING1 agonists currently in clinical trials** | | | | | | |
| ADU-S100 | Synthetic CDN analog | Antitumor activity | B16 mouse models | Failed in phase II clinical trial | | 198 |
| ADU-CL-20 | Synthetic CDN analog | Antitumor activity | Metastatic/recurrent HNSCC | Phase II | NCT03937141 | |
| MK-1454 | Synthetic CDN analog | Antitumor activity | Advanced solid tumors or lymphomas | Phase I | NCT03010176 | |
| MK-2118 | Synthetic CDN analog | Antitumor activity | Advanced solid tumors or lymphomas | Phase I | NCT03249792 | |
| BMS-986301 | Undisclosed | Antitumor activity | Advanced solid cancers | Phase I | NCT03956680 | |
| GSK3745417 | diABZI-like | Antitumor activity | Advanced solid tumors | Phase I | NCT03843359 | |
| SB-11285 | CDN analog | Antitumor activity | Advanced solid tumors | Phase I | NCT04096638 | |
| IMSA-101 | cGAMP analog | Antitumor activity | Advanced solid tumors | Phase VII | NCT04020185 | |
| E7766 | Synthetic CDN analog | Antitumor activity | Advanced solid tumors; lymphomas | Phase I | NCT04144140 | |
| **STING1 inhibitors** | | | | | | |
| H-151 | | Blocks palmitoylation of STING1 | | | | 199 |
| C-178 | | Blocks palmitoylation of STING1 | | | | 199 |
| C-176 | | Blocks palmitoylation of STING1 | | | | 199 |
| CI8 | | Blocks cGAMP-induced IRF3 production | | | | 200 |
| Astin-C | | Blocks recruitment of IRF3 to STING1 | | | | 201 |
biomarkers that can be used to monitor STING1-dependent autophagy and cell death? What are the activities and side effects of different STING1 drugs? How can we develop a STING1-dependent combination drug strategy for tumor treatment?

ADDITIONAL INFORMATION

Competing interests: The authors declare no competing interests.

REFERENCES

1. Tang, D. et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158–175 (2012).
2. Medzhitov, R. & Janeway, C. Jr. Innate immunity. N. Engl. J. Med. 343, 338–344 (2000).
3. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008).
4. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
5. Sun, W. et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc. Natl Acad. Sci. USA 106, 8653–8658 (2009).
6. Zhong, B. et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29, 538–550 (2008).
7. Sun, L. et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
8. Motwani, M., Pesirisid, S. & Fitzgerald, K. A. DNA sensing by the cGAS-STING pathway in health and disease. Nat. Rev. Genet. 20, 657–674 (2019).
9. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).
10. Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515–518 (2011).
11. Dey, B. et al. A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nat. Med. 21, 401–406 (2015).
12. Hofhner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).
13. Ablasser, A. et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503, 530–534 (2013).
14. Ritchie, C. et al. SLC19A1 is an importer of the immunotransmitter cGAMP. Mol. Cell. 75, 372–381.e375 (2019).
15. Lahey, L. J. et al. LRRC8A/C/E heteromeric channels are ubiquitous transporters of cGAMP. Mol. Cell. 80, 578–591 (2020).
16. Torralba, D. et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts. Nat. Commun. 9, 2658 (2018).
17. Zeng, L. et al. ALK is a therapeutic target for lethal sepsis. Sci. Transl. Med. 9, eaan5689 (2017).
18. Ergun, S. L., Fernandez, D., Weiss, T. M. & Li, L. STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell 178, 290–301.e210 (2019).
19. Zhang, B. C. et al. STEEP mediates STING ER exit and activation of signaling. Nat. Immunol. 21, 868–879 (2020).
20. Sun, M. S. et al. TMD2/ID2 potentiates cellular IFN responses to DNA viruses by reinforcing MITA dimerization and facilitating its trafficking. Cell Rep. 25, 3086–3098.e3083 (2018).
21. Gui, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262–266 (2019).
22. Dobbs, N. et al. STING activation by translocation from the ER is associated with infection and autoimmune inflammatory disease. Cell Host Microbe 18, 157–168 (2015).
23. Mukai, K. et al. Activation of STING requires palmitoylation at the Golgi. Nat. Commun. 7, 11932 (2016).
24. Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).
25. Zhang, C. et al. Structural basis of STING binding with and phosphorylation by TBK1. Nature 567, 394–398 (2019).
26. Corrales, L. et al. Innate immune signalling and regulation in cancer immunotherapy. Cell Res. 27, 96–108 (2017).
27. Gonugunta, V. et al. Trafficking-mediated STING degradation requires sorting to acidified endolysosomes and can be targeted to enhance anti-tumor response. Cell Rep. 21, 3234–3242 (2017).
28. Li, L. et al. Hydrolysis of 2′-O-methyl cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
29. Zhang, H. et al. TMEM173 drives lethal coagulation in sepsis. Cell Host Microbe 27, 556–570.e556 (2020).
30. Heipertz, E. L., Harper, J. & Walker, W. E. STING and TRIF contribute to mouse sepsis, depending on severity of the disease model. Shock 47, 621–631 (2017).
31. Zhou, B. et al. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling. Nat. Microbiol. 5, 1576–1587 (2020).
122. Miao, L. et al. Targeting the STING pathway in tumor-associated macrophages.

108. Guicciardi, M. E. & Gores, G. J. Life and death by death receptors.

97. Vanden Berghe, T. et al. Regulated necrosis: the expanding network of non-

109. White, M. J. et al. Apoptotic caspases suppress mtDNA-induced STING-mediated

82. Chung, K. W. et al. Mitochondrial damage and activation of the STING pathway

114. Chung, K. W. et al. Mitochondrial damage and activation of the STING pathway

138. Zhang, X. et al. mtDNA-STING pathway promotes necroptosis-dependent

61. Galluzzi, L. et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dys-

135. Schock, S. N. et al. Induction of necrotic cell death by viral activation of the

132. McComb, S. et al. Type-I interferon signaling through ISGF3 complex is required

136. Brault, M. et al. Intracellular Nucleic Acid Sensing Triggers Necroptosis through

142. Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical in

105. Julien, O. & Wells, J. A. Caspases and their substrates.

107. Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by
159. Wu, Z. et al. Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl Acad. Sci. USA 116, 2996–3005 (2019).
160. Bai, Y. et al. Lipid storage and lipophagy regulates ferroptosis. Biochem. Biophys. Res. Commun. 508, 997–1003 (2019).
161. Jia, M. et al. Redox homeostasis maintained by GPX4 facilitates STING activation. Nat. Immunol. 21, 727–735 (2020).
162. Dai, E. et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat. Commun. 11, 6339 (2020).
163. Jiang, R. et al. BECN1 is a new driver of ferroptosis. Autophagy 14, 2173–2175 (2018).
164. Wu, J. et al. STING-dependent induction of lipid peroxidation mediates intestinal ischemia-reperfusion injury. Free Radic. Biol. Med. 163, 135–140 (2020).
165. Liu, J. et al. The dark side of ferroptosis in pancreatic cancer. Onc Immunology 10, 1868691 (2021).
166. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2823–2837 (2004).
167. Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461–465 (2017).
168. Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466–470 (2017).
169. Cao, D. et al. Structural basis for nucleosome-mediated inhibition of cGAS activity. Cell Res. 30, 1088–1097 (2020).
170. Kujiri, T. et al. Structural basis for the inhibition of cGAS by nucleosomes. Science 370, 455–458 (2020).
171. Pathare, G. R. et al. Structural mechanism of cGAS inhibition by the nucleosome. Nature 587, 668–672 (2020).
172. Michalski, S. et al. Structural basis for sequestration and autoinhibition of cGAS by chromatin. Nature 587, 678–682 (2020).
173. Zhao, B. et al. The molecular basis of tight nuclear tethering and inactivation of cGAS. Nature 587, 673–677 (2020).
174. Zierhut, C. et al. The cytoplasmic DNA sensor cGAS promotes mitotic cell death. Cell 178, 302–315 (2019).
175. Lohard, S. et al. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nat. Commun. 11, 259 (2020).
176. Chattopadhyay, S. et al. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 20, 2246–2256 (2020).
177. Klarquist, J. et al. STING-mediated DNA sensing promotes antritumor and autoimmune responses to dying cells. J. Immunol. 193, 6124–6134 (2014).
178. Zhou, C. et al. Transfer of cGAMP into bystander cells via LRRC8 volume-regulated anion channels augments STING-mediated interferon responses and anti-viral immunity. Immunity 52, 767–781 (2020).
179. Lemos, H. et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 76, 2076–2081 (2016).
180. Motedayen Aval, L. Pease, J. E., Sharma, R. & Pinato, D. J. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J. Clin. Med. 9, 3323 (2020).
181. Lemos, H. et al. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity. J. Immunother. Cancer. 8, e001182 (2020).
182. Berger, G., Marloye, M. & Lawler, S. E. Pharmacological modulation of the STING pathway for cancer immunotherapy. Trends Mol. Med. 25, 412–427 (2019).
183. Le Naour, J. et al. Trial watch: STING agonists in cancer therapy. Oncoimmunology 9, 1777624 (2020).
184. Tansakul, M. et al. Deficiency of STING promotes collagen-specific antibody production and B cell survival in collagen-induced arthritis. Front. Immunol. 11, 1101 (2020).
185. Wu, J., Dobbs, N., Yang, K. & Yan, N. Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 53, 115–126.e115 (2020).
186. Wang, Z. & Celis, E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol. Immunother. 64, 1057–1066 (2015).
187. Chandra, D. et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2, 901–910 (2014).
188. Ohkuri, T. et al. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol. Immunother. 66, 705–716 (2017).
189. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).
190. Skouboe, M. K. et al. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. PLoS Pathog. 14, e1006976 (2018).
191. Lara, P. N. J. et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vandetanib (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 2965–2971 (2011).
192. Kerr, D. J. & Kaye, S. B. Flavone acetic acid–preclinical and clinical activity. Eur. J. Cancer Clin. Oncol. 25, 1271–1272 (1989).
193. Cavelar, T. et al. Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J. 32, 1440–1450 (2013).
194. Ovalle-Magallanes, B., Eugenio-Perez, D. & Pedraza-Chaverri, J. Medicinal properties of mangosteen (Garcinia mangostana L.): a comprehensive update. Food Chem. Toxicol. 109, 102–122 (2017).
195. Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
196. Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaab6098 (2020).
197. Chin, E. N. et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369, 993–999 (2020).
198. Sivick, K. E. et al. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated antitumor immunity. Cell Rep. 25, 3074–3085 (2018).
199. Haag, S. M. et al. Targeting STING with covalent small-molecule inhibitors. Nature 559, 269–273 (2018).
200. Shi, T. et al. Discovery of a novel cGAMP competitive ligand of the inactive form of STING. ACS Med. Chem. Lett. 10, 92–97 (2019).
201. Li, S. et al. The cyclopeptide astin C specifically inhibits the innate immune CDSN sensor STING. Cell Rep. 25, 3405–3421 (2018).